Drug products: Ketotifen STADA, Zaditen, Zaditen Defiante, Zaditen Novartis, Zaditen®, Zalerg, Zasten
ATC code: R06AX17, S01GX08
Substances: ketotifen, ketotifen fumarate
There are no published controlled studies on differences between the sexes regarding efficacy, safety and pharmacokinetics of ketotifen.
The prevalence of self-reported allergic rhinoconjunctivitis symptoms was in a Swedish population study (n=10,670) similar in men and women . Ketotifen is topically used in allergic conjunctivitis. Systemic exposure of ketotifen in topical administration can be expected to be very low or absent based on a study where plasma levels were not detectable when given the ophtalmic route .
Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding pharmacokinetics and dosing of ketotifen have been found.
No studies with a clinically relevant sex analysis regarding effects of ketotifen have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of ketotifen have been found.
Reproductive health issues
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2022-08-04
- Olsson P, Berglind N, Bellander T, Stjärne P. Prevalence of self-reported allergic and non-allergic rhinitis symptoms in Stockholm: relation to age, gender, olfactory sense and smoking. Acta Otolaryngol. 2003;123(1):75-80. PubMed
- Zaditen (ketotifen). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-10-08, cited 2022-08-04]
- Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.] länk
Reviewed by: Diana Rydberg, Carl-Olav Stiller, Pauline Raaschou
Approved by: Karin Schenck-Gustafsson